(90)Y-Ibritumomab tiuxetan followed by reduced-intensity conditioning and allogeneic stem-cell transplantation in patients with advanced follicular lymphoma

RIC HSCT is a potentially curative therapeutic option for patients with advanced FL but disease relapse remains the most common cause of failure. Radioimmunoconjugates administered prior to RIC allogeneic HSCT may enhance cytoreduction and allow more time for graft versus lymphoma effect to develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Abou-Nassar, Karim E., Stevenson, Kristen E., Antin, Joseph H., McDermott, Kathleen, Ho, Vincent T., Cutler, Corey S., LaCasce, Ann S., Jacobsen, Eric D., Fisher, David C., Soiffer, Robert J., Alyea, Edwin P., Koreth, John, Freedman, Arnold S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139703/
https://www.ncbi.nlm.nih.gov/pubmed/21258420
http://dx.doi.org/10.1038/bmt.2010.339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139703/
https://www.ncbi.nlm.nih.gov/pubmed/21258420
http://dx.doi.org/10.1038/bmt.2010.339

Ejemplares similares